PRIMARY OBJECTIVE:
I. To determine the improvement in hair density as determined by the Dean scale score in patients with chemotherapy-induced alopecia following treatment with low-level light therapy (LLLT) and topical minoxidil versus topical minoxidil alone.
SECONDARY OBJECTIVES:
I. To determine the improvement in hair density and hair diameter as determined by trichoscopic evaluation in patients with chemotherapy-induced alopecia following treatment with LLLT and topical minoxidil versus topical minoxidil alone.
II. To determine the change in the quality-of-life Chemotherapy Alopecia Distress Scale (CADS) questionnaire score in patients with chemotherapy-induced alopecia following treatment with LLLT and topical minoxidil versus topical minoxidil alone.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive minoxidil topically to the scalp daily for 6 months in the absence of unacceptable toxicity.
ARM II: Patients receive minoxidil topically to the scalp daily and undergo low-level red-light therapy with the Revian RED LED-light cap over 10 minutes daily for 6 months in the absence of unacceptable toxicity.
After completion of study intervention, patients are followed up at 12 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients will be Ohio State University patients \> 18 years old
Patients will have a diagnosis of breast cancer, stages I-IV
Patients will have been treated with a chemotherapy regimen containing either an anthracycline or taxane
Patients will have a loss of at least 50% of the hair on the scalp by the final chemotherapy infusion
Patients will NOT be pregnant or nursing women
Patients will NOT have a history of scarring/cicatricial alopecia or alopecia areata
Patients will NOT have a known sensitivity to minoxidil
Patients will NOT have ongoing treatment with an antibody-drug conjugate or immunotherapy
